Recent Updates
Recently added Catalysts
QDEL Positive Sentiment

QUIDELORTHO AND BÜHLMANN LABORATORIES AG ANNOUNCE AVAILABILITY OF FECAL CALPROTECTIN (FCAL®) TURBO AND FECAL PANCREATIC ELASTASE (FPELA®) TURBO ASSAYS ON VITROS™ SYSTEMS AS A MICROTIP™ PARTNERSHIP ASSAY (MPA) QuidelOrtho Corporation (Nasdaq: QDEL) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and...

Monday, July 14, 2025 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: QuidelOrtho Corporation and BÜHLMANN Laboratories AG have launched two new assays, the fCAL turbo and fPELA turbo, on QuidelOrtho's VITROS Systems. These assays are designed to improve the diagnosis of inflammatory bowel disease (IBD) and pancreatic insufficiency. The fCAL turbo assay helps differentiate IBD from irritable bowel syndrome, while the fPELA turbo assay assesses pancreatic function.
Price reaction · baseline $30.34 (2025-07-11 close) · 1 other QDEL headline(s) in the window, move may be shared
day 0 close · peak
-4.9%

Market Sentiment Analysis

POSITIVE FACTORS

  • Introduction of new assays enhances diagnostic capabilities.
  • Partnership with BÜHLMANN Laboratories AG expands testing options.
  • Assays support critical diagnoses for gastrointestinal conditions.

Full Press Release Details

Gastrointestinal biomarker tests enhance patient diagnosis of IBD and pancreatic insufficiency on leading clinical chemistry platforms
SAN DIEGO , July 14, 2025 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL ) ("QuidelOrtho") and BÜHLMANN Laboratories AG today announced the availability of the BÜHLMANN fCAL turbo and fPELA turbo assays on QuidelOrtho's VITROS Systems as an MPA. Both particle-enhanced turbidimetric immunoassays, the fCAL turbo assay for fecal calprotectin measurement aids in the diagnosis of inflammatory bowel disease (IBD) and its differentiation from irritable bowel syndrome, and the fPELA turbo assay for fecal pancreatic elastase aids in the determination of pancreatic insufficiency.

Frequently Asked Questions

What are the new assays launched by QuidelOrtho?

QuidelOrtho launched the fCAL turbo and fPELA turbo assays.

What conditions do the new assays help diagnose?

The assays aid in diagnosing inflammatory bowel disease and pancreatic insufficiency.

On which systems are the new assays available?

The assays are available on QuidelOrtho's VITROS Systems.

What is the purpose of the fCAL turbo assay?

The fCAL turbo assay measures fecal calprotectin to aid in diagnosing IBD.

How does the fPELA turbo assay assist clinicians?

The fPELA turbo assay helps determine pancreatic insufficiency.

ShareAdd on Google
Tags: QDEL Viatris Investor Conferences Healthcare QuidelOrtho BÜHLMANN Laboratories fCAL turbo fPELA turbo IBD diagnosis
Last updated: Jul 14, 2025

Biotech snapshot

Cash runway
$123M liquidity · $7M/mo burn
~17 mo
Low dilution risk